Close

Alkermes plc (ALKS) Tops Q3 EPS by 3c

October 29, 2015 7:08 AM EDT

Alkermes plc (NASDAQ: ALKS) reported Q3 EPS of ($0.18), $0.03 better than the analyst estimate of ($0.21). Revenue for the quarter came in at $152.7 million versus the consensus estimate of $151.77 million.

“Earlier this month, the FDA approved ARISTADA™ as the first long-acting atypical antipsychotic for the treatment of schizophrenia with both once-monthly and six-week dosing. Our nationwide commercial launch is underway and we are delighted to bring this important new treatment option to patients and the treatment community,” said Richard Pops, Chief Executive Officer of Alkermes. “Alkermes has a number of important milestones ahead that will drive the growth of the company. Based on our recent discussions with the FDA, we have determined the design of the pivotal programs for both ALKS 3831 in schizophrenia and ALKS 8700 in multiple sclerosis and expect to initiate both before year-end. The pivotal program for ALKS 5461 in major depressive disorder is advancing rapidly, and we expect data from the first core efficacy study in the first quarter of 2016.”

“We are pleased by our solid financial performance during the third quarter and are on track with our financial expectations for the remainder of 2015. The approval of ARISTADA further strengthens our commercial portfolio and represents a major financial opportunity for Alkermes,” commented James Frates, Chief Financial Officer of Alkermes. “Heading into 2016, we are well-positioned to invest in our development plans for our late-stage pipeline, the launch of ARISTADA and drive the growth of VIVITROL®.”

For earnings history and earnings-related data on Alkermes plc (ALKS) click here.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Earnings, Management Comments

Related Entities

Earnings